[FG] Hartmann Karin

Roth, Michèle et al. (2024) ‘Characterization of the gut and skin microbiome over time in young children with IgE-mediated food allergy’, Nutrients, 16(22). Available at: https://doi.org/10.3390/nu16223942.

Valent, P. et al. (2024) ‘Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM’, The Journal of Allergy and Clinical Immunology: In Practice [Preprint]. Available at: https://doi.org/10.1016/j.jaip.2024.08.044.

Pascal, Mariona et al. (2024) ‘Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An EAACI position paper’, Allergy [Preprint]. Available at: https://doi.org/10.1111/all.16246.

Schmid, Alicia et al. (2024) ‘Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM’, Blood Advances, 8(11), pp. 2890–2900. Available at: https://doi.org/10.1182/bloodadvances.2024012756.

Baldrich, Adrian et al. (2024) ‘Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency’, Journal of Clinical Immunology, 44(3). Available at: https://doi.org/10.1007/s10875-024-01667-z.

Bellutti Enders, Felicitas et al. (2024) ‘Orale Immuntherapie bei Nahrungsmittelallergien: Praktische Empfehlungen für das Patientenmanagement in der Schweiz’, Paediatrica, 35(1). Available at: https://doi.org/10.35190/paediatrica.d.2024.1.6.

Worm, Margitta et al. (2024) ‘Occupational anaphylaxis—Data from the anaphylaxis registry’, Allergy: European Journal of Allergy and Clinical Immunology, 79(3), pp. 702–710. Available at: https://doi.org/10.1111/all.15974.

Codilupi, Tamara et al. (2024) ‘Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable’, Clinical Cancer Research. 01.02.2024, 30(3), pp. 586–599. Available at: https://doi.org/10.1158/1078-0432.ccr-23-0163.

Stivala, Simona et al. (2024) ‘Data from Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable’. American Association for Cancer Research (AACR). Available at: https://doi.org/10.1158/1078-0432.c.7054101.v1.

Baldrich, Adrian et al. (2024) ‘Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency’, Journal of Clinical Immunology, 44. Available at: https://doi.org/10.1007/s10875-024-01667-z.

Bozic, Manuela et al. (2024) ‘Evaluation of the cow’s milk and hen’s egg ladder in daily practice: a parent perspective’, Klinische Pädiatrie [Preprint].

Breiding, Maria et al. (2024) ‘Safety of oral immunotherapy for cashew nut and peanut allergy in children – a retrospective single-centre study’, Swiss medical weekly [Preprint].

Burgener-Gasser, Anne-Valérie et al. (2024) ‘Assessing the rationale of prescribing carbapenems among hospitalized patients with documented penicillin allergy: Implications for stewardship’, Antimicrobial Stewardship and Healthcare Epidemiology, 4. Available at: https://doi.org/10.1017/ash.2024.5.

Curatolo, R. et al. (2024) ‘Delayed-type hypersensitivity reaction to oral intake of trometamol’, Contact Dermatitis [Preprint]. Available at: https://doi.org/10.1111/cod.14585.

Greiner, Georg et al. (2024) ‘Tumor necrosis factor α promotes clonal dominance of KIT D816V⁺ cells in mastocytosis: role of survivin and impact on prognosis’, Blood, 143, pp. 1006–1017. Available at: https://doi.org/10.1182/blood.2023020515.

Höfer, V. et al. (2024) ‘Fatal and Near-Fatal Anaphylaxis: Data From the European Anaphylaxis Registry and National Health Statistics’, Journal of Allergy and Clinical Immunology: In Practice, 12(1), pp. 96–105.e8. Available at: https://doi.org/10.1016/j.jaip.2023.09.044.

Niedoszytko, M. et al. (2024) ‘Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry’, Allergy: European Journal of Allergy and Clinical Immunology [Preprint]. Available at: https://doi.org/10.1111/all.16132.

Schmid-Grendelmeier, P. et al. (2024) ‘Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies’, Allergy: European Journal of Allergy and Clinical Immunology, 79(1), pp. 174–183. Available at: https://doi.org/10.1111/all.15952.

Zwimpfer, T.A. et al. (2024) ‘Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers’, Cancer Medicine, 13(1). Available at: https://doi.org/10.1002/cam4.6840.

Bellutti Enders F et al. (2023) ‘Alpha-gal syndrome initially misdiagnosed as chronic spontaneous urticaria in a pediatric patient: a case report and review of the literature’, Journal of Medical Case Reports, 17(1). Available at: https://doi.org/10.1186/s13256-022-03718-8.

Konantz M et al. (2023) ‘Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis’, Journal of Allergy and Clinical Immunology, 152(4), pp. 1019–1024. Available at: https://doi.org/10.1016/j.jaci.2023.07.001.

Dölle-Bierke S et al. (2023) ‘Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry’, Journal of Allergy and Clinical Immunology: In Practice, 11(7), pp. 2069–2079.e7. Available at: https://doi.org/10.1016/j.jaip.2023.03.026.

Hartmann, Karin and Wassmer, Hanna (2023) ‘Childhood mastocytosis Kindliche Mastozytose’, Dermatologie, 74(7). Available at: https://doi.org/10.1007/s00105-023-05174-x.

Limberg MM et al. (2023) ‘Eosinophils, Basophils, and Neutrophils in Bullous Pemphigoid’, Biomolecules, 13(7). Available at: https://doi.org/10.3390/biom13071019.

Valent P et al. (2023) ‘European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives’, Journal of Allergy and Clinical Immunology: In Practice, 11(6), pp. 1706–1717. Available at: https://doi.org/10.1016/j.jaip.2023.02.021.

Castells, Mariana et al. (2023) ‘Avapritinib versus Placebo in Indolent Systemic Mastocytosis’, NEJM Evidence, 2(6). Available at: https://doi.org/10.1056/evidoa2200339.

Kennedy VE et al. (2023) ‘Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry’, Blood Advances, 7(9), pp. 1713–1724. Available at: https://doi.org/10.1182/bloodadvances.2022008292.

Akin C. et al. (2023) ‘Legends of Allergy and Immunology—Dean D. Metcalfe’, Allergy: European Journal of Allergy and Clinical Immunology, 78(5), pp. 1395–1396. Available at: https://doi.org/10.1111/all.15657.

Bellutti Enders, F. et al. (2023) ‘Immunothérapie orale et allergie alimentaire : commentaires pratiques pour la prise en charge des patients en Suisse’, Paediatrica, 35(1). Available at: https://doi.org/10.35190/paediatrica.f.2024.1.6.

Konantz M et al. (2023) ‘MRGPRX2: A novel biomarker in mastocytosis?’, Journal of Allergy and Clinical Immunology: In Practice, 11(2), pp. 669–671. Available at: https://doi.org/10.1016/j.jaip.2022.10.053.

Lübke J et al. (2023) ‘Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis’, Journal of Allergy and Clinical Immunology: In Practice, 11(2), pp. 581–590.e5. Available at: https://doi.org/10.1016/j.jaip.2022.10.051.

Giannetti M.P. et al. (2023) ‘Outcomes of COVID-19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders’, Allergy: European Journal of Allergy and Clinical Immunology, 78(1), pp. 301–304. Available at: https://doi.org/10.1111/all.15476.

Hartmann, Karin et al. (2023) ‘Dermatologische Klinik des Universitätsspitals Basel’, Aktuelle Dermatologie, 49(10), pp. 422–434. Available at: https://doi.org/10.1055/a-2122-7078.

Hundt, J.E. et al. (2023) ‘A life for autoimmune blistering diseases: in memoriam Detlef Zillikens’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1291590.

Schwaab, Juliana, Horny, Hans-Peter and Hartmann, Karin (2023) ‘Diagnosis and treatment of systemic mastocytosis’, Best Practice Onkologie, 18, pp. 524–533. Available at: https://doi.org/10.1007/s11654-023-00531-7.

Valent, P. et al. (2023) ‘The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT’, Journal of Allergy and Clinical Immunology: In Practice, 11, pp. 3010–3020. Available at: https://doi.org/10.1016/j.jaip.2023.08.008.

Schwaab J., Horny H.-P. and Hartmann K. (2023) ‘Diagnosis and treatment of systemic mastocytosis’, Onkologie, 29, pp. 323–328. Available at: https://doi.org/10.1007/s00761-022-01269-7.

Wassmer H. and Hartmann K. (2023) ‘Mastocytosis in children’, Dermatologie [Preprint]. Available at: https://doi.org/10.1007/s00105-023-05168-9.

Wassmer H. and Hartmann K. (2023) ‘Mastocytosis in children’, Monatsschrift fur Kinderheilkunde, 171, pp. 430–438. Available at: https://doi.org/10.1007/s00112-023-01757-z.

Kirsch M et al. (2022) ‘Presence of neoplastic mast cells in ascites in advanced systemic mastocytosis’, Journal of Allergy and Clinical Immunology: In Practice, 10(11), pp. 3035–3038.e1. Available at: https://doi.org/10.1016/j.jaip.2022.07.014.

Roth MS et al. (2022) ‘Safe administration of subsequent mRNA COVID-19 vaccine doses following a possible allergic reaction to the first dose’, Journal of the European Academy of Dermatology and Venereology, 36(11), pp. e880–e883. Available at: https://doi.org/10.1111/jdv.18387.

Bergmann C et al. (2022) ‘AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper’, Allergy: European Journal of Allergy and Clinical Immunology, 77(9), pp. 2594–2617. Available at: https://doi.org/10.1111/all.15255.

Cumin C et al. (2022) ‘Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways’, Cell Reports, 40(7), p. 111181. Available at: https://doi.org/10.1016/j.celrep.2022.111181.

Gotlib J et al. (2022) ‘Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis’, Journal of Allergy and Clinical Immunology: In Practice, 10(8), pp. 2025–2038.e1. Available at: https://doi.org/10.1016/j.jaip.2022.05.034.

Hoermann G et al. (2022) ‘Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group’, Journal of Allergy and Clinical Immunology: In Practice, 10(8), pp. 1953–1963. Available at: https://doi.org/10.1016/j.jaip.2022.03.001.

Jennings SV et al. (2022) ‘Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond’, Journal of Allergy and Clinical Immunology: In Practice, 10(8), pp. 2039–2051. Available at: https://doi.org/10.1016/j.jaip.2022.06.018.

Pyatilova P et al. (2022) ‘Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium’, Journal of Allergy and Clinical Immunology: In Practice, 10(8), pp. 2015–2024. Available at: https://doi.org/10.1016/j.jaip.2022.05.037.

Sotlar K et al. (2022) ‘Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group’, Journal of Allergy and Clinical Immunology: In Practice, 10(8), pp. 1986–1998.e2. Available at: https://doi.org/10.1016/j.jaip.2022.05.036.

Valent P et al. (2022) ‘Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium’, Journal of Allergy and Clinical Immunology: In Practice, 10(8), pp. 1941–1950. Available at: https://doi.org/10.1016/j.jaip.2022.05.007.

Valent P et al. (2022) ‘Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice’, Journal of Allergy and Clinical Immunology: In Practice, 10(8), pp. 1999–2012.e6. Available at: https://doi.org/10.1016/j.jaip.2022.03.007.

Bianco G et al. (2022) ‘Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.’, 5(1). Available at: https://doi.org/10.1038/s42003-022-03612-5.

Valent P et al. (2022) ‘Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022’, International Archives of Allergy and Immunology, 183(7), pp. 693–705. Available at: https://doi.org/10.1159/000524532.

Bellutti Enders, F., Roth, M. and Roethlisberger, S. (2022) ‘Arzneimittelallergien bei Kindern: was sollten Kinderärzte wissen?’, Paediatrica, 33(2). Available at: https://doi.org/10.35190/paediatrica.d.2022.2.1.

Bellutti Enders, Felicitas, Roth, Michèle and Roethlisberger, Samuel (2022) ‘Allergies médicamenteuses – que doit savoir le pédiatre ?’, Paediatrica, 33(2). Available at: https://doi.org/10.35190/paediatrica.f.2022.2.1.

Arock M et al. (2022) ‘Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022’, Journal of Allergy and Clinical Immunology, 149(6), pp. 1855–1865. Available at: https://doi.org/10.1016/j.jaci.2022.04.004.

Redhu D et al. (2022) ‘Mast cells instruct keratinocytes to produce thymic stromal lymphopoietin: Relevance of the tryptase/protease-activated receptor 2 axis’, Journal of Allergy and Clinical Immunology, 149(6), pp. 2053–2061.e6. Available at: https://doi.org/10.1016/j.jaci.2022.01.029.

Valent P et al. (2022) ‘Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?’, Journal of Allergy and Clinical Immunology, 149(6), pp. 1866–1874. Available at: https://doi.org/10.1016/j.jaci.2022.04.003.

Bianco G et al. (2022) ‘GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.’, Communications biology, 5(1), p. 373. Available at: https://doi.org/10.1038/s42003-022-03296-x.

Nsiah-Dosu S et al. (2022) ‘Mast cell-deficient mice Mcpt5Cre/Dicer fl/fl redefine the role of mast cells in experimental bullous pemphigoid’, Skin Health and Disease, 2(1), p. e70. Available at: https://doi.org/10.1002/ski2.70.

Zanotti R et al. (2022) ‘Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis’, Leukemia, 36(2), pp. 516–524. Available at: https://doi.org/10.1038/s41375-021-01406-y.

Cajacob, Lucian, Chantraine, Sibylla and Hartmann, Karin (2022) ‘Allergic Contact Stomatitis’. Springer International Publishing, pp. 423–426. Available at: https://doi.org/10.1007/978-3-030-82804-2_39.

Atallah I et al. (2021) ‘Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene’, Clinical Genetics, 99(6), pp. 780–788. Available at: https://doi.org/10.1111/cge.13942.

Aberer, Elisabeth et al. (2021) ‘Clinical impact of skin lesions in mastocytosis: a multicenter study of the European Competence Network on Mastocytosis (ECNM)’, The Journal of Investigative Dermatology, 141(7), pp. 1719–1727. Available at: https://doi.org/10.1016/j.jid.2020.12.030.

Bonadonna, Patrizia et al. (2021) ‘COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)’, The Journal of Allergy and Clinical Immunology. In Practice, 9(6), pp. 2139–2144. Available at: https://doi.org/10.1016/j.jaip.2021.03.041.

Bürgler, A. et al. (2021) ‘Rationale and design of a panel study investigating six health effects of airborne pollen: the EPOCHAL study’, Frontiers in Public Health, 9, p. 689248. Available at: https://doi.org/10.3389/fpubh.2021.689248.

Dannenmann, Benjamin et al. (2021) ‘iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia’, Cell Stem Cell, 28(5), pp. 906–922.e6. Available at: https://doi.org/10.1016/j.stem.2021.03.023.

Fuchs, David et al. (2021) ‘Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin’, The Journal of Allergy and Clinical Immunology: In Practice, 9(4), pp. 1705–1712.e4. Available at: https://doi.org/10.1016/j.jaip.2020.12.022.

Giannetti, Matthew P. et al. (2021) ‘COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms’, The Journal of Allergy and Clinical Immunology: In Practice, 9(5), pp. 2083–2086. Available at: https://doi.org/10.1016/j.jaip.2021.02.023.

Gotlib, Jason et al. (2021) ‘Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin’, Expert Opinion on Biological Therapy, 21(4), pp. 487–498. Available at: https://doi.org/10.1080/14712598.2021.1837109.

Gülen, Theo et al. (2021) ‘Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review’, The Journal of Allergy and Clinical Immunology. In Practice, 9(11), pp. 3918–3928. Available at: https://doi.org/10.1016/j.jaip.2021.06.011.

Hirsiger, J. R. et al. (2021) ‘Anaphylaxis to goat’s and sheep’s milk in an adult tolerant to cow milk: A sensitization profile study’, Journal of Investigational Allergology & Clinical Immunology, 32(2), pp. 154–156. Available at: https://doi.org/10.18176/jiaci.0721.

Jamiolkowski, Dagmar et al. (2021) ‘Structured diagnostic assessment of hand eczema in cleaning workers’, Journal der Deutschen Dermatologischen Gesellschaft, 19(5), pp. 672–676. Available at: https://doi.org/10.1111/ddg.14452.

Jamiolkowski, Dagmar et al. (2021) ‘Strukturierte diagnostische Abklärung eines Handekzems bei Reinigungsfachkräften’, JDDG - Journal of the German Society of Dermatology, 19(5), pp. 672–678. Available at: https://doi.org/10.1111/ddg.14452_g.

Klimek, Ludger et al. (2021) ‘Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI’, Allergo Journal International, 30(3), pp. 79–95. Available at: https://doi.org/10.1007/s40629-021-00165-7.

Klimek, Ludger et al. (2021) ‘Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA)’, Allergo Journal, 30(2), pp. 51–55. Available at: https://doi.org/10.1007/s40629-020-00160-4.

Kluin-Nelemans, Hanneke C. et al. (2021) ‘Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis’, Theranostics, 11(1), pp. 292–303. Available at: https://doi.org/10.7150/thno.51872.

Landerer, Henrik et al. (2021) ‘Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia’, Journal of visualized experiments [Preprint], (168). Available at: https://doi.org/10.3791/61803.

Lange, Magdalena et al. (2021) ‘Molecular background, clinical features and management of pediatric mastocytosis: Status 2021’, International journal of molecular sciences, 22(5), p. 2586. Available at: https://doi.org/10.3390/ijms22052586.

Peters, Franziska et al. (2021) ‘Detection of the Germline KIT S476I Mutation in a Kindred with Familial Mastocytosis associated with Gastrointestinal Stromal Tumors’, The Journal of Allergy and Clinical Immunology. In Practice, 9(5), pp. 2123–2125.e1. Available at: https://doi.org/10.1016/j.jaip.2020.12.049.

Schmitt, Anja et al. (2021) ‘Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL’, Blood, 138(10), pp. 871–884. Available at: https://doi.org/10.1182/blood.2020009404.

Schürch, Christoph et al. (2021) ‘SRP54 mutations induce Congenital Neutropenia via dominant-negative effects on XBP1 splicing’, Blood, 137(10), pp. 1340–1352. Available at: https://doi.org/10.1182/blood.2020008115.

Sonay, Ali Yasin et al. (2021) ‘Biodegradable Harmonophores for Targeted High-Resolution; In Vivo; Tumor Imaging’, ACS Nano, 15(3), pp. 4144–4154. Available at: https://doi.org/10.1021/acsnano.0c10634.

Steveling-Klein, Esther Helen et al. (2021) ‘Management of hypersensitivity reactions to nondextran iron products: new insights into predisposing risk factors’, The Journal of Allergy and Clinical Immunology: In Practice, 9(6), pp. 2406–2414.e2. Available at: https://doi.org/10.1016/j.jaip.2021.01.009.

Thomas, Zita-Rose Manjaly et al. (2021) ‘Contact dermatitis to hair cosmetics: current diagnostic recommendations’, Journal der Deutschen Dermatologischen Gesellschaft (DDG), 19(12), pp. 1729–1734. Available at: https://doi.org/10.1111/ddg.14544.

Thomas, Zita-Rose Manjaly et al. (2021) ‘Kontaktekzem auf Haarkosmetikprodukte: Aktuelle Empfehlungen zur Diagnostik’, JDDG - Journal of the German Society of Dermatology, 19(12), pp. 1729–1735. Available at: https://doi.org/10.1111/ddg.14544_g.

Trachsel, Tina et al. (2021) ‘Cannabisallergie’, Swiss Medical Forum, 21(25-26), pp. 449–451. Available at: https://doi.org/10.4414/smf.2021.08677.

Valent, Peter et al. (2021) ‘Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal’, HemaSphere, 5(11), p. e646. Available at: https://doi.org/10.1097/hs9.0000000000000646.

Hamarsheh S et al. (2020) ‘Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation’, Nature Communications, 11(1), p. 1659. Available at: https://doi.org/10.1038/s41467-020-15497-1.

Arnone, Marlon et al. (2020) ‘Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity’, Cancers, 12(12), p. 3742. Available at: https://doi.org/10.3390/cancers12123742.

Castro, Carla Noemi et al. (2020) ‘NCKAP1L defects lead to a novel syndrome combining immunodeficiency, lymphoproliferation, and hyperinflammation’, Journal of Experimental Medicine, 217(12), p. e20192275. Available at: https://doi.org/10.1084/jem.20192275.

Ernst, N. et al. (2020) ‘Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris’, Journal of the European Academy of Dermatology and Venereology, 35(2), pp. 486–492. Available at: https://doi.org/10.1111/jdv.16780.

Ferastraoaru, D. et al. (2020) ‘AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer - a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)’, Clinical and Translational Allergy, 10(1), p. 32. Available at: https://doi.org/10.1186/s13601-020-00335-w.

Goldust, Mohamad et al. (2020) ‘Utility and risk of dermatologic medications during the COVID-19 pandemic’, Dermatologic Therapy, p. e13833. Available at: https://doi.org/10.1111/dth.13833.

Hartmann, Karin et al. (2020) ‘Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis’, Journal of Allergy and Clinical Immunology, 146(2), pp. 356–366.e4. Available at: https://doi.org/10.1016/j.jaci.2020.03.044.

Huang, Yen-Lin et al. (2020) ‘Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis’, eLife, 9, p. e59442. Available at: https://doi.org/10.7554/elife.59442.

Jamiolkowski, Dagmar et al. (2020) ‘Multilocular bullous fixed drug eruption elicited by paracetamol and migraine attacks, but not by paracetamol alone’, Contact Dermatitis, 83(3), pp. 233–234. Available at: https://doi.org/10.1111/cod.13567.

Kluin-Nelemans, Hanneke C. et al. (2020) ‘Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry’, Leukemia, 34(4), pp. 1090–1101. Available at: https://doi.org/10.1038/s41375-019-0632-4.

Landolina, Nadine et al. (2020) ‘Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells’, Pharmacological Research, 158, p. 104682. Available at: https://doi.org/10.1016/j.phrs.2020.104682.

Manjaly Thomas, Zita-Rose et al. (2020) ‘Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities’, Journal Of Allergy And Clinical Immunology, 146(4), pp. 786–789. Available at: https://doi.org/10.1016/j.jaci.2020.07.008.

Maurer, Marcus et al. (2020) ‘Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020’, International Archives of Allergy and Immunology, 181(5), pp. 321–333. Available at: https://doi.org/10.1159/000507218.